

# Aisha Lateef

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2796372/publications.pdf>

Version: 2024-02-01

38  
papers

1,504  
citations

567144

15  
h-index

454834

30  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1595  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1615-1621.	0.5	421
2	Managing lupus patients during pregnancy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 435-447.	1.4	194
3	Unmet medical needs in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2012, 14, S4.	1.6	127
4	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017, 19, 62.	1.6	100
5	Systemic Lupus Erythematosus and Pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 215-226.	0.8	97
6	Management of pregnancy in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2012, 8, 710-718.	3.5	73
7	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology, The</i> , 2019, 1, e95-e102.	2.2	65
8	Hormone replacement and contraceptive therapy in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2012, 38, J170-J176.	3.0	58
9	Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. <i>Clinical Rheumatology</i> , 2009, 28, 1449-1452.	1.0	47
10	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e24-e30.	2.2	45
11	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 260.	1.6	44
12	A Flow Cytometry-Based Assay for High-Throughput Detection and Quantification of Neutrophil Extracellular Traps in Mixed Cell Populations. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 268-278.	1.1	41
13	Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 746-757.	0.9	26
14	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	0.9	24
15	Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 798-803.	1.6	18
16	“Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
17	Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. <i>Pharmacogenomics</i> , 2017, 18, 881-890.	0.6	15
18	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	0.9	12

#	ARTICLE	IF	CITATIONS
19	A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study. <i>Rheumatology</i> , 2015, 54, 1161-1169.	0.9	10
20	Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1911-1918.	0.9	10
21	Predicting flares in patients with stable systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 91-97.	1.6	9
22	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational <i>study</i>. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9
23	A meta-analysis of clinical manifestations in asian systemic lupus erythematosus: The effects of ancestry, ethnicity and gender. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151932.	1.6	8
24	Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio reflect disease activity and flares in patients with systemic lupus erythematosus—AA prospective study. <i>Joint Bone Spine</i> , 2022, 89, 105342.	0.8	7
25	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
26	Impact of inpatient Care in Emergency Department on outcomes: a quasi-experimental cohort study. <i>BMC Health Services Research</i> , 2017, 17, 555.	0.9	5
27	Acute medical unit: experience from a tertiary healthcare institution in Singapore. <i>Singapore Medical Journal</i> , 2018, 59, 510-513.	0.3	5
28	Case reports of transient loss of vision and systemic lupus erythematosus. <i>Annals of the Academy of Medicine, Singapore</i> , 2007, 36, 146-9.	0.2	5
29	Quality improvement at an acute medical unit in an Asian Academic Center: A mixed methods study of nursing work dynamics. <i>Nursing Outlook</i> , 2020, 68, 169-183.	1.5	3
30	Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 1121-1126.	0.8	3
31	Infections and musculoskeletal conditions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 187-188.	1.4	0
32	OP0246—ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .		0
33	OP0330—#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0
34	THU0253—EFFECT OF GLUCOCORTICOIDS ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0
35	FRI0221—CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY: CASE SERIES. , 2019, , .		0
36	25—Prospective multicenter validation of the lupus low disease activity state (LLDAS) treatment target. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	26â€¦Comparison of effects of DORIS remission and lupus low disease activity state (LLDAS) on disease outcomes in a multinational prospective study. , 2019, , .		0
38	Reply on: A Meta-Analysis of Clinical Manifestations in Asian Systemic Lupus Erythematosus: The Effects of Ancestry, Ethnicity and Gender. Seminars in Arthritis and Rheumatism, 2022, 55, 152009.	1.6	0